IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1643

In re Application of: Michael SCHIRNER et al.

Serial No.: 10/088,866

Filed: July 2, 2002 Examiner: Sheela J. Huff

For: ANTIBODY-DYE CONJUGATES FOR BINDING TO TARGET STRUCTURES OF ANGIOGENESIS IN ORDER TO INTRAOPERATIVELY DEPICT TUMOR PERIPHERIES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

		Inder 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information is closure statement is filed:			
		within three months of the filing date of a national application other than a CPA under § 1.53(d);			
		within three months of the actual filing date of the national phase of a PCT application; OR			
		before the mailing of a first substantive office action (including after filing of an RCE).			
\boxtimes	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of:				

a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

		is accompanied by:				
		\boxtimes	the statement as specified in 37 C.F.R. § 1.97(e) set out below;			
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or			
			payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
	Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the date of the following actions which have not been withdrawn:					
		a final	action under 37 C.F.R. § 1.113;			
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);			
		OR a r	notice of allowance under 37 C.F.R. § 1.311;			
	AND i	is filed o	on or before payment of the issue fee; AND is accompanied by:			
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).			
Staten	ients Ui	nder 37	C.F.R. 1.97(e)			
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited Materials						
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or 1449 by the applicant; see 37 C.F.R. § 1.98(d).			
		_	s of materials listed but not attached were cited in an international search dated			
			2			

	\boxtimes	Not required by 37 CFR § 1.98. (U.S. 4,341,223 A)			
	\boxtimes	Copies of the materials listed are attached (except for the foregoing).			
Non-E	nglish I	_anguage References			
		An English-language search report or equivalent paper from a foreign pate office is provided indicating the relevance of the cited reference(s).			
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:			
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art 			
		O = non-written disclosure			
		P = intercalated document T = document cited to understand the theory or principle underlying the			
		invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date			
		D = cited in the application L = cited for another reason			
		L = cited for another reason & = publication of member of same patent family			
		Translation of other relevant information on foreign search report			
0.1					
Other	Informa	<u>ition</u>			
Payme	ent of Fe	ees Due (If Any):			
	A che	ck for \$ covering the fee identified above is attached.			
	Payme	Payment by credit card via EFS for \$ covering the fee identified above.			
	Please	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.			

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1869

Date: October 15, 2008

AJZ:klb